Patient Support Services Contact Us

Investors

Overview

Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

News
08/01/19
– Company is Profitable and Cash flow Positive from Operations for Second Quarter –  – UDENYCA ® is the Market Leading Pegfilgrastim Biosimilar with Approximately 13% Market Share – REDWOOD CITY, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.
07/29/19
REDWOOD CITY, Calif. , July 29, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that the United States Court of Appeals for the Federal Circuit has affirmed the decision of the United States District Court for the District of Delaware
07/19/19
REDWOOD CITY, Calif. , July 19, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective July 18, 2019 , the compensation committee of the company’s board of directors granted five new employees options to purchase an aggregate of 125,000 shares of the
07/08/19
REDWOOD CITY, Calif. , July 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that UDENYCA® preliminary unaudited net sales for the quarter that ended June 30, 2019 are expected to be in the range of $79.0 million to $84.0 million .
Events & Presentations